About 100 reports

  • Key market highlights

Oral iron drugs have been linked with adverse gastrointestinal side effects and require multiple daily doses.

  • Endocrine Disease
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • Galenica Group
  • SANOFI

IT IS INVOLVED IN DISCOVERING, DEVELOPING, MANUFACTURING, AND COMMERCIALIZING PRESCRIPTION MEDICINES FOR THE TREATMENT OF ONCOLOGY, CARDIOVASCULAR AND METABOLIC, RESPIRATORY, INFECTION, GASTROINTESTINAL, AND NEUROSCIENCE DISEASES GLOBALLY.

  • Endocrine Disease
  • World
  • AstraZeneca PLC
  • Horizon Pharma plc
  • Sanofi S.A.

GASTROINTESTINAL EVENTS SUCH AS NAUSEA AND DIARRHEA OCCURRED MOST FREQUENTLY.

  • Endocrine Disease
  • Asia
  • World
  • Novo Nordisk Group
  • Sanofi S.A.

FERRIC CITRATE BINDS TO PHOSPHATE IN THE GASTROINTESTINAL TRACT AND DECREASES SERUM PHOSPHORUS CONCENTRATION THROUGH INHIBITING PHOSPHATE ABSORPTION INTO THE BODY.

  • Endocrine Disease
  • World
  • AbbVie Inc.
  • Novartis AG
  • OPKO Health, Inc.

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Endocrine Disease
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Dipep

Gastrointestinal events such as nausea and diarrhea occurred most frequently.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 1.1 I.V. Iron Application Areas
  • 3.1 Growth Drivers

Hemodialysis patients keep on loosing iron incessantly through gastrointestinal bleeding, blood drawing, and mostly from the hemodialysis treatment itself.

  • Endocrine Disease
  • Actavis plc
  • AMAG Pharmaceuticals, Inc.
  • Galenica Group
  • Vifor Pharma

GASTROINTESTINAL ADVERSE EFFECTS WERE MORE COMMON IN THE VICTOZA TREATMENT ARM COMPARED TO BYDUREON.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • T1DM Therapeutics Market, Global, All Pipeline Products, Discovery Phase, 2015

It manifests as dysfunction of one or more organ systems including the cardiovascular, gastrointestinal, genitourinal, sudomotor and ocular systems.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group

Gastrointestinal events such as nausea and diarrhea occurred most frequently.

  • Endocrine Disease
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

CLINICAL TRIALS HAVE FOUND FOSRENOL TREATMENT TO BE GENERALLY WELL TOLERATED, WITH ADVERSE EVENTS TYPICALLY BEING GASTROINTESTINAL.

  • Endocrine Disease
  • Forecast
  • Amgen Inc.
  • Keryx Biopharmaceuticals, Inc.
  • OPKO Health, Inc.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • PEPTIDE THERAPEUTICS IN METABOLIC DISORDERS: TECHNOLOGY PLATFORMS
  • 1. CONJU33

THIS IS DONE TO DECREASE THE PROBABILITY OF GASTROINTESTINAL SYMPTOMS.

  • Endocrine Disease
  • Glucagon Like Peptide 1 Receptor Activator
  • United States
  • LipimetiX Development LLC
  • Novartis AG

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

The two conditions are characterized by chronic inflammation of the gastrointestinal tract.

  • Cancer
  • Endocrine Disease
  • HIV AIDS
  • Specialty Hospital
  • GlobalData's company

Systemic amyloidosis (AL amyloidosis or just primary amyloidosis) is a medical condition which involves the mesenchymal tissue, the tongue, heart, gastrointestinal tract, and skin.

  • Endocrine Disease
  • Pathology
  • Asia
  • Forecast

The gastrointestinal therapeutics market recorded ## partnership deals and six licensing deals worth USD##. ## billion in Q## 2016.

  • Endocrine Disease
  • Pharmaceutical
  • World
  • Deals & Alliance
  • AstraZeneca PLC

PRIOR TO THAT, SHE WAS A PRODUCT DEVELOPMENT ENGINEER AT AN NIH-FUNDED SBIR FIRM, WHERE SHE WORKED ON GASTROINTESTINAL BIOPSY AND ORTHOPEDIC DEVICES.

  • Endocrine Disease
  • Europe
  • B. Braun Melsungen AG
  • ConvaTec Inc.
  • Covidien plc

Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Immunology and Undisclosed which include indications Obesity, Dyslipidemia, Hyperlipidemia, Inflammation, Non-Alcoholic Steatohepatitis (NASH), Type ## Diabetes and Unspecified.

  • Endocrine Disease
  • Oleochemicals
  • United States
  • World
  • Product Initiative
  • 5.6.1 PHARMACEUTICALS & HEALTHCARE, GLOBAL, METABOLIC DISORDERS DEALS, 2016 BY QUARTER

FIGURE ## SHOWS THE TOTAL NUMBER OF GASTROINTESTINAL THERAPY DEALS WITH DISCLOSED DEAL VALUES.

  • Endocrine Disease
  • Hospital
  • World
  • Company
  • Deals & Alliance
  • DRUGS TO INHIBIT ABHD6 FOR GASTROINTESTINAL AND METABOLIC DISORDERS - DRUG PROFILE
  • ASSESSMENT BY MOLECULE TYPE
  • Diabetes
  • Endocrine Disease
  • World
  • Product Initiative
  • PhaseBio Pharmaceuticals, Inc.
  • SYNTHETIC PEPTIDES FOR CARDIOVASCULAR, GASTROINTESTINAL, METABOLIC DISORDERS AND INFECTIOUS DISEASE - DRUG PROFILE
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H1 2016
  • Cardiovascular Disease
  • Endocrine Disease
  • United States
  • Company
  • Product Initiative
  • HYPOPARATHYROIDISM - PIPELINE BY SHIRE PLC, H2 2017
  • HYPOPARATHYROIDISM - PIPELINE BY PHARIS BIOTEC GMBH, H2 2017

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Endocrine Disease
  • Therapy
  • Europe
  • United States
  • NPS Pharmaceuticals, Inc.
  • Secondary Hyperparathyroidism - Pipeline by Shire Plc, H2 2017

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Endocrine Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • HYPERINSULINEMIA - PIPELINE BY EIGER BIOPHARMACEUTICALS INC, H1 2017
  • EXENDIN-(9-39) - DRUG PROFILE

This gastrointestinal hormone, GLP-## is released after meal.

  • Endocrine Disease
  • United States
  • World
  • Product Initiative
  • XOMA Corporation
  • 1.2 Types
  • 1.1 Introduction

It is beneficial in stabilizing gastrointestinal problems, as well as neurological symptoms.

  • Endocrine Disease
  • Pharmaceutical
  • World
  • Forecast
  • Prothena Corporation plc
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2017 (CONTD..1), H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY UNIVERSITIES/INSTITUTES, H2 2017

It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies

  • Cardiovascular Disease
  • Endocrine Disease
  • Therapy
  • United States
  • Product Initiative